tim-pasik-1
22 July 2022Insurance

Markel taps insider to lead commercial casualty product lines

Specialist insurer  Markel Corporation has tapped a long-serving senior executive to lead its commercial casualty product lines.

Tim Pasik (pictured) has been appointed managing director, commercial casualty product lines leader for  Markel Specialty's insurance operations.

In his new role, Pasik will provide oversight for  Markel Specialty's commercial primary and excess – retail and wholesale – product lines. He will report to Rodrigues and is based in  Markel's New York, New York office.

Pasik joined  Markel in 2014 and most recently served as managing director, commercial excess casualty, wholesale. He has nearly 40 years of insurance industry experience and has developed underwriting guidelines, established rating parameters, and set authorities for field underwriters.

Alan Rodrigues, executive underwriting officer, casualty, said: "We're looking forward to continuing to drive profitable growth for  Markel's commercial casualty product lines. Tim's leadership qualities, ability to build relationships, and strategic problem solving will help support our customers in finding the best possible solutions for their risks."

Did you get value from this story? Sign up to our free daily newsletters and get stories like this sent straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Insurance
9 October 2026   Benign weather and private line gains lift Tryg to record Q3 performance.
Insurance
9 October 2026   Policy counts show a split in commercial and household demand as NFIP loses ground.
Insurance
9 October 2026   Data will help underwriters assess fleet selection, claims costs and emerging exposures.